The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer

키워드

참고문헌 (39)

1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
2. Fox JG, "Inflammation, atrophy, and gastric cancer", J Clin Invest, 117, pp.60~69 (2007)
3. Correa P, "Helicobacter pylori and gastric carcinogenesis", Am J Surg Pathol, 19(1), pp.37~43 (1995)
4. Lauren P, "The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
5. Gregory Lauwers G, "Gastric cancer", World Health Orga, 22, pp.745~755 (2009)
6. Liu YJ, "Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer", World J Gastroenterol, 11, pp.6601~6606 (2005)
7. Joo M, "Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis", Anticancer Res, 23(2), pp.1581~1588 (2003)
8. Heider KH, "Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa", Cancer Res, 53, pp.4197~4203 (1993)
9. Tahara E, "Genetic pathways of two types of gastric cancer", IARC Sci Publ, (157), pp.327~349
10. Müller W, "Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer", J Pathol, 183, pp.222~227
11. Mayer B, "De-novo expression of CD44 and survival in gastric cancer", Lancet, 342, pp.1019~1022 (1993)
12. Günthert U, "A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells", Cell, 65, pp.13~24 (1991)
13. 김민아, "Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach", CANCER, 103(7), pp.1439~1446, JOHN WILEY SONS INC
14. Houghton J, "Stem cells and cancer", Semin Cancer Biol, 17, pp.191~203 (2007)
15. Lapidot T, "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice", Nature, 367, pp.645~648 (1994)
16. Al-Hajj M, "Prospective identification of tumorigenic breast cancer cells", Proc Natl Acad Sci U S A, 100, pp.3983~3988 (2003)
17. Li C, "Identification of pancreatic cancer stem cells", Cancer Res, 67, pp.1030~1037 (2007)
18. Prince ME, "Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma", Proc Natl Acad Sci U S A, 104, pp.973~978 (2007)
19. Dalerba P, "Phenotypic characterization of human colorectal cancer stem cells", Proc Natl Acad Sci U S A, 104, pp.10158~10163 (2007)
20. Collins AT, "Prospective identification of tumorigenic prostate cancer stem cells", Cancer Res, 65, pp.10946~10951 (2005)
21. Takaishi S, "Identification of gastric cancer stem cells using the cell surface marker CD44", Stem Cells, 27, pp.1006~1020 (2009)
22. Kim H, "CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation", Arch Biochem Biophys, 310, pp.504~507 (1994)
23. Ishimoto T, "CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth", Cancer Cell, 19, pp.387~400 (2011)
24. Ishimoto T, "CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis", Cancer Sci, 101, pp.673~678 (2010)
25. Györffy B, "Biomarkers downstream of RAS: a search for robust transcriptional targets", Curr Cancer Drug Targets, 10, pp.858~868 (2010)
26. Phillips TM, "The response of CD24(-", low), J Natl Cancer Inst, pp.2006, 98[DOI]
27. Winder T, "Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma", Int J Cancer, 129, pp.1096~1104 (2011)
28. Valentine A, "FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism", Clin Cancer Res, 17, pp.1044~1056 (2011)
29. Van Phuc P, "Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells", Onco Targets Ther, 4, pp.71~78 (2011)
30. Misra S, "Delivery of CD44 shRNA", nanoparticles within cancer cells: perturbation of hyaluronan, + MICE, pp.J Biol Chem, 2009[DOI]
31. Misra S, "Hyaluronan-CD44 interactions as potential targets for cancer therapy", FEBS J, 278, pp.1429~1443 (2011)
32. Serafino A, "CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis", Curr Cancer Drug Targets, 11, pp.572~585 (2011)
33. Li SD, "CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases", Mol Pharm, 7, pp.280~290 (2010)
34. Liu C, "The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44", Nat Med, 17, pp.211~215 (2011)
35. Börjesson PK, "Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma", Clin Cancer Res, 9, pp.3961~3972 (2003)
36. Verel I, "Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts", Int J Cancer, 99, pp.396~402 (2002)
37. Tijink BM, "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus", Clin Cancer Res, 12, pp.6064~6072 (2006)
38. Stroomer JW, "Safety and biodistribu tion of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients", Clin Cancer Res, 6, pp.3046~3055 (2000)
39. Rupp U, "Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study", Anticancer Drugs, 18, pp.477~485 (2007)

관련 논문AI추천